The Metabolic Front.

The firmest boundary on the site.

This is a page about science, not a page about treatment. Cancer is the one area where the stakes make caution non-negotiable, so let it be said plainly, up front, and again at the end: nothing here is cancer treatment, a protocol, or a reason to change, delay or refuse anything an oncologist recommends. The drugs described are prescription oncology medicines used under specialist care; the metabolic ideas are about how cancer works and, separately, about the terrain you can tend to lower risk — never about treating a cancer you already have. If you or someone you love has a diagnosis, the single most useful thing on this page is this sentence: follow your oncology team.

The most widely used cancer-imaging scan in the world is the FDG-PET. FDG is fluorodeoxyglucose — radioactive glucose. It's injected, it travels where glucose is being consumed most greedily, and the scanner photographs the glow. Tumours light up because they take up glucose far faster than the tissue around them — the very phenomenon Warburg described in the 1920s, now the routine way cancer is found, staged and tracked.[1]

Sit with that. Oncology's workhorse scan doesn't look for a gene or a shape. It looks for an appetite — a cancer's abnormal hunger for sugar. The metabolic signature isn't a theory waiting for acceptance; it's bright enough to build a hospital department around. Move the slider and watch the scan do what it does.

Insulin is a growth signal.

The oncometabolite story is about a gene gone wrong inside the cell. The insulin story is about the message arriving from outside it. Insulin — and its cousin IGF-1 — aren't only about blood sugar; they are among the body's oldest commands to grow and build. They deliver that command through a signalling relay called PI3K (phosphoinositide 3-kinase), the discovery that won Lewis Cantley a share of science's top prizes, and which runs down through AKT and mTOR to tell a cell to take up nutrients, grow, and divide.

That relay is one of the most frequently hijacked pathways in all of cancer. And it can be lit not only by a mutation but by the signal itself: chronically high insulin is a standing "grow" instruction that a tumour carrying the right wiring is only too glad to obey. It's the molecular bridge between the whole-body fire this series describes — the insulin switch stuck on — and a cell that wants to proliferate.

The most striking evidence came from Cantley's own lab. Drugs that block PI3K were disappointing in people, and the reason turned out to be a feedback loop: blocking PI3K spikes blood sugar, the body answers with a flood of insulin, and that insulin reaches straight past the drug to switch the pathway back on. In mice, lowering the insulin response — including with diet — restored the drugs' power.[5] The body's fuel signal wasn't a bystander to the cancer drug; it was fighting it.

The people carrying it.

It would be easy to imagine metabolic oncology as the project of a lone maverick. It isn't. The modern revival runs through some of the most mainstream names in cancer biology: Lewis Cantley (PI3K), Craig Thompson, Matthew Vander Heiden and Chi Van Dang, whose work re-established that the way a cancer rewires its metabolism to fuel its own growth is not a side effect but a core part of the disease.[1] Their landmark review — tellingly titled Understanding the Warburg Effect — reframed Warburg's hundred-year-old puzzle as the metabolic requirements of a cell built to divide.

That lineage, from Warburg's Nobel through the decades of neglect to today's drugs and labs, is told in full in the companion piece: The Warburg Lineage. This page is the view from the clinic; that one is the view from the century.

Warburg's curiosity, in the clinic.

What Otto Warburg saw down a microscope in the 1920s is now the glow on a hospital scan, a mutation with three drugs aimed at it, and a signalling pathway that ties a cancer cell's hunger to the body's own command to grow. The metabolic view earned its place the slow, ordinary way — through imaging, trials and approvals — not through slogans. That's exactly why it can be held calmly: it needs no overclaiming, and it tolerates none. The science is strong enough to stand, and disciplined enough to know where it stops — at the edge of the clinic, where the oncologist takes over.

Cancer's metabolism, from a shelved idea to the pharmacy — and still, always, a doctor's ground to treat.